NASDAQFinancialsInsurance - LifeSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AAME yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve and maintain compliance with Nasdaq listing requirements | The company targets compliance with Nasdaq listing rules to avoid delisting risks. | Under Pressure | Receipt of new Nasdaq delisting notice or actual delisting | Delisting initiated vs No notices Oct 16, 2026 Staff Determination initiated delisting process following Aug 20 notice for late 10-Q/10-K filings. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making financial company with volatile management, not a proven durable compounder. Its thesis is in a watch state: recent performance is weak versus its industry cohort, and the evidence does not show a fresh break in the thesis.
AAME is described as cheap versus peers, but valuation rose recently and the expectations gap is negative, suggesting current expectations may still be demanding. The priced-in assessment is tagged as justified, with low fragility, though model confidence is medium.
Near term, weak financial performance and recent negative listing-rule notices leave execution risks unresolved. Management priorities include regaining Nasdaq filing compliance, achieving sustained profitable growth, and maintaining strong operating cash flow, all still marked as watch items.
The multi-year view depends on progress toward compliance and sustained profitable growth. Near term, a guidance cut or falling rates would be negative factors, while continued earnings strength and higher guidance from sector bellwethers could support sector momentum.
Over the next one to three years, AAME’s cheap-versus-peers valuation is set against losses, weak performance, and unresolved compliance and execution risks. The thesis remains watchful and hinges on measurable progress in those areas. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Atlantic American aims to maintain positive operating cash flow near $9.3M quarterly. |
| Broken |
| operating cash flow falls below $9M in any quarter |
Cash from operations: $17.676M FY2025-Q4; GAAP. Published target: >= $9.28M per quarter. Target period is not explicitly aligned with this observation. Oct 16, 202617,676,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve revenue growth near 8.5% next year | Analysts expect about 8.5% revenue growth next year. | Intact | YoY revenue growth falls below 6% in FY26 | Revenue growth: 4.53% FY2025-Q4; GAAP. Published target: >= 8% YoY revenue growth. Annual target cannot be compared with a quarterly or TTM observation. Oct 16, 20264.530718 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.